These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22284690)

  • 1. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms.
    Pak D; Vineberg K; Feng F; Ten Haken RK; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1528-33. PubMed ID: 22284690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer.
    Laidley HM; Noble DJ; Barnett GC; Forman JR; Bates AM; Benson RJ; Jefferies SJ; Jena R; Burnet NG
    Radiat Oncol; 2018 May; 13(1):84. PubMed ID: 29728105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lhermitte's Sign following VMAT-Based Head and Neck Radiation-Insights into Mechanism.
    Ko HC; Powers AR; Sheu RD; Kerns SL; Rosenstein BS; Krieger SC; Mourad WF; Hu KS; Gupta V; Bakst RL
    PLoS One; 2015; 10(10):e0139448. PubMed ID: 26448647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.
    Ho KF; Marchant T; Moore C; Webster G; Rowbottom C; Penington H; Lee L; Yap B; Sykes A; Slevin N
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e375-82. PubMed ID: 22197229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
    Bhide SA; Davies M; Burke K; McNair HA; Hansen V; Barbachano Y; El-Hariry IA; Newbold K; Harrington KJ; Nutting CM
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1360-8. PubMed ID: 20338474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
    Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
    Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.
    Semrau R; Temming S; Preuss SF; Klubmann JP; Guntinas-Lichius O; Müller RP
    Strahlenther Onkol; 2011 Oct; 187(10):645-50. PubMed ID: 21947123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
    J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal cord planning risk volumes for intensity-modulated radiation therapy of head-and-neck cancer.
    Breen SL; Craig T; Bayley A; O'Sullivan B; Kim J; Jaffray D
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):321-5. PubMed ID: 16377418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer.
    Hansen EK; Bucci MK; Quivey JM; Weinberg V; Xia P
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):355-62. PubMed ID: 16256277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
    Vlacich G; Diaz R; Thorpe SW; Murphy BA; Kirby W; Sinard RJ; Shakhtour B; Shyr Y; Murphy P; Netterville JL; Yarbrough WG; Cmelak AJ
    Oncologist; 2012; 17(5):673-81. PubMed ID: 22550060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
    Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer.
    Mul VE; de Jong JM; Murrer LH; van den Ende PL; Houben RM; Lacko M; Lambin P; Baumert BG
    Strahlenther Onkol; 2012 Jan; 188(1):71-6. PubMed ID: 22194023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
    Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer.
    Hunter KU; Fernandes LL; Vineberg KA; McShan D; Antonuk AE; Cornwall C; Feng M; Schipper MJ; Balter JM; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):676-82. PubMed ID: 24035328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer.
    Diaz R; Jaboin JJ; Morales-Paliza M; Koehler E; Phillips JG; Stinson S; Gilbert J; Chung CH; Murphy BA; Yarbrough WG; Murphy PB; Shyr Y; Cmelak AJ
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):468-76. PubMed ID: 19577867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study.
    Nicolini G; Ghosh-Laskar S; Shrivastava SK; Banerjee S; Chaudhary S; Agarwal JP; Munshi A; Clivio A; Fogliata A; Mancosu P; Vanetti E; Cozzi L
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):553-60. PubMed ID: 22386376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.